Video
Author(s):
Neeraj Agarwal, MD, a professor of Medicine at the Huntsman Cancer Institute, University of Utah, discusses health-related quality of life (HRQoL) and patient-reported outcomes from the phase 3 TITAN trial of apalutamide (Erleada) in patients with metastatic castration-sensitive prostate cancer (mCSPC).
The TITAN trial (NCT02489318) randomized 1052 patients with mCSPC in a 1:1 ratio to receive apalutamide plus androgen-deprivation therapy (ADT) or placebo plus ADT. The results showed that adding apalutamide to ADT reduced the risk of death by 35% versus ADT alone.
Based on the efficacy and safety data from the primary TITAN analysis, the FDA approved apalutamide for the treatment of patients with mCSPC.
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.